An alternative approach with a low dose and prolonged chemotherapy for palliative treatment of locally advanced, metastatic or recurrent squamous cell head and neck cancer

摘要

It is expected that about 65,000 new patients will be diagnosed with head and neck cancer in 2017 in the United States. Patients with recurrent or advanced or metastatic head and neck do not have good survival due to aggressive and recurrent nature of this cancer. Moreover, cumulative and residual toxicities from previous and ongoing treatments significantly impede quality of remaining part of their life. Currently available chemotherapeutic regimens for this group are derived from the treatments used for the potentially curable disease. These regimens and associated toxicity are obviously not the best matches for the treatment with palliative intent. We here present a retrospective study where we used dose-adjusted chemotherapy specifically for palliative treatment this sub-group of head and neck cancer patients. Study population was identified from the University of Florida, and IRB approval was obtained. We used currently available and approved chemotherapeutic agents (including Taxols, Platins, 5-Fluorouracil and Epidermal Growth Factor Receptor inhibitors) for treatment of head and neck cancer but dose-adjusted at approximate 50% dose of currently recommended doses. We then gave personalized doses for a prolonged period by titrating doses based on response and tolerability of each patient. Data was collected for treatment, response, side effects, and outcomes. KM analysis was performed for survival data. Total of 32 patients were included in this study with a median age of 65.2?years and a median follow-up of 10.1?months. 62.5% (n?=?20) had locally advanced disease and rest had metastatic disease. 37.5% (n?=?12) had new disease while rest had recurrent cancer. Of 32 patients, 14 patients received TPF based while 18 patients received PFE based chemotherapy. Total of 270 chemotherapy cycles were delivered among these 32 patients. They received a median of 9?cycles (range 3–14) over a median of 6.2?months (range 1.8–21.1). With this treatment approach, we noted median progression-free survival of 14.0?months and median overall survival of 15.7?months. Notable grade 3 toxicities were generalized fatigue in 12.5% (n?=?4), nausea/vomiting in 6.3% (n?=?2), diarrhea in in 6.3% (n?=?2), mouth soreness in 6.3% (n?=?2), rash in 3.1% (n?=?1), neutropenia in 18% (n?=?6) and anemia in 15.6% (n?=?5) while notable grade 4 toxicities were neutropenia and anaphylaxis in 3.1% (n?=?1) patient each. With this personalized approach, we noticed minimal side effects, able to deliver prolonged therapy and obtained comparable results to previous studies.